News Release
<< Back
Newly Published Data Demonstrates 85% Eradication of Ulcer Causing Bacteria
H. pylori has long been known as a common pathogen associated with gastric ulcers and related dyspeptic symptoms in many infected patients. If H. pylori is left untreated, it can damage the stomach and small intestine wall causing peptic ulcer disease, specifically duodenal ulcers. Symptoms of H. pylori-induced duodenal ulcers generally surface in adults and may include burning pain in the abdomen, nausea, vomiting, bloating, and weight loss.
Currently, the use of clarithromycin-based triple therapy has the support of organizational bodies in gastroenterology. Over the last 10 years, early recommendations to use clarithromycin-based triple therapy have been challenged by some sources and based on the premise that resistance is increasing.
This study, led by
Despite predictions from other sources in the last decade that clarithromycin-based treatments are becoming less effective, based on the results of this study, patients with a positive diagnosis of H. pylori could expect an 85% or better eradication rate when treated with clarithromycin-based triple therapy.
About Omeclamox®-Pak (omeprazole, clarithromycin, amoxicillin)
Omeclamox®-Pak is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori. Omeprazole is an antisecretory drug, which works by decreasing the amount of acid the stomach produces. Clarithromycin and amoxicillin are antibacterial drugs, which inhibit the growth of bacteria allowing the stomach lining to heal. Omeclamox-Pak is contraindicated in patients with a history of hypersensitivity to omeprazole, any macrolide antibiotic or penicillin. The safety and effectiveness of Omeclamox-Pak in the pediatric population has not yet been established. For full prescribing information, visit www.omeclamox.com.
About
The Company's portfolio of
- Acetadote® (acetylcysteine) Injection, for the treatment of acetaminophen poisoning;
- Caldolor® (ibuprofen) Injection, for the treatment of pain and fever;
- Kristalose® (lactulose) for Oral Solution, a prescription laxative, for the treatment of chronic and acute constipation;
- Omeclamox®-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease;
- Vaprisol® (conivaptan) Injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia;
- Ethyol® (amifostine) Injection, for the reduction of xerostomia (dry mouth) in patients undergoing post-operative radiation treatment for head and neck cancer and the renal toxicity associated with the administration of cisplatin in patients with advanced ovarian cancer;
- Totect®(dexrazoxane hydrochloride) Injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy in case of extravasation (drug leakage from the bloodstream into the tissues).
Cumberland's pipeline of product candidates includes:
- Hepatoren® (ifetroban) Injection, a Phase II candidate for the treatment of critically ill patients suffering from liver and kidney failure associated with hepatorenal syndrome ("HRS");
- Boxaban®(ifetroban) Oral Capsules, a Phase II candidate for the treatment of asthma patients with aspirin-exacerbated respiratory disease ("AERD");
- Vasculan®(ifetroban) Oral Capsules, a Phase II candidate for the treatment of patients with systemic sclerosis (SSc) form of autoimmune disease;
- Portaban® (ifetroban) Injection and Oral Capsules, a Phase II candidate for the treatment of patients with portal hypertension associated with liver disease;
- RediTrex™ (methotrexate) Injection, an approval submission candidate for the treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis, as well as severe disabling psoriasis.
For more information on Cumberland's approved products, including full prescribing information, please visit the individual product websites, links to which can be found on the Company's website www.cumberlandpharma.com
View original content with multimedia:http://www.prnewswire.com/news-releases/newly-published-data-demonstrates-85-eradication-of-ulcer-causing-bacteria-300619074.html
SOURCE
News Provided by Acquire Media